Fall in Degussa's pharmaceutical first half sales:
This article was originally published in Clinica
Sales at Degussa's pharmaceuticals division, which includes amalgam manufacturer Degussa Dental, fell 1% to DM 1,073 million ($700 million) in the first half of fiscal 1996 (ended March 31st). The German group's sales decreased 5% to DM 6,900 million, while pre-tax income rose 2% to DM 186 million. The company says the weak domestic economic climate contributed to the falling sales.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.